Related Experiment Video
Updated: Apr 19, 2026
06:46
A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
Published on: July 5, 2022
3.4K
Development and validation of a cost-utility model for Type 1 diabetes mellitus
S Wolowacz1, I Pearson1, P Shannon2
1Health Economics, RTI Health Solutions, Manchester.
Diabetic Medicine : a Journal of the British Diabetic Association
|December 9, 2014
Summary
A new health economic model accurately predicts long-term complications of Type 1 diabetes mellitus, aiding cost-effectiveness analyses of new treatments. This model considers HbA1c and hypoglycemic events for improved diabetes management strategies.
Area of Science:
- Health economics
- Diabetes mellitus research
- Biostatistics
Background:
- Type 1 diabetes mellitus (T1DM) management requires evaluating new interventions for long-term cost-effectiveness.
- Assessing interventions necessitates accurate prediction of T1DM-related complications and hypoglycemic events.
Purpose of the Study:
- To develop a robust health economic model for T1DM interventions.
- To evaluate cost-effectiveness based on long-term complication prediction (mean HbA1c) and hypoglycemic event impact.
Main Methods:
- Systematic review to identify T1DM complications and incidence data.
- Individual patient simulation model incorporating 9 key complications.
- Development of risk equations using published data (HbA1c, age, diabetes duration).
- Internal and external validation comparing model predictions with observed outcomes.
Main Results:
- Model predictions showed <2% deviation in internal validation.
- Model predictions showed <8% deviation in external validation (absolute difference in cumulative incidence).
Conclusions:
- The developed model uses high-quality, recent data specific to T1DM.
- Model validation confirms its accuracy, with deviations under 8% from expected values.
- The model is suitable for evaluating the cost-effectiveness of T1DM interventions.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
01:22Diabetes Mellitus: Overview and Type I Subtype
6.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
6.5K
01:22Diabetes Mellitus: Type 2 and Gestational
5.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.9K
01:19Type I Diabetes III: Clinical Manifestations
9
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the...
9
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
4
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated...
4
01:26Type I Diabetes II: Pathophysiology
6
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular...
6